Eco Animal Health set to beat full-year expectations
ECO Animal Health Group
Eco Animal Health announced on Thursday that it was now expecting to exceed market expectations for the financial year ending 31 March.
FTSE AIM All-Share
Pharmaceuticals & Biotechnology
The AIM-traded company, which specialises in developing, registering, and marketing pharmaceutical products for the global animal health industry, reported strong trading in its final quarter.
It said demand for its flagship product, Aivlosin, had been particularly strong in China and Asia.
As a result, the board said it now expected that revenue and EBITDA would be “slightly ahead” of market expectations.
“Our business has delivered good progress in key international markets especially Asia,” said chief executive officer David Hallas.
“We look forward to providing a further update following the completion of the financial year.”
At 1513 GMT, shares in Eco Animal Health Group were up 8.16% at 106p.
Reporting by Josh White for Sharecast.com.